References

1. 1. Деев Р.В., Мавликеев М.О., Бозо И.Я., Пулин А.А., Еремин И.И. 2014. Генно-клеточная терапия наследственных заболеваний мышечной системы: современное состояние вопроса. Гены и клетки. Т 9. № 4. С. 6. (Deev R.V., Mavlikeev M.O., Bozo I.Ya., Pulin A.A., Eremin I.I. 2014. Gene- and cell-based therapy of muscle system hereditary disorders: state-of-art. Genes Cells V. 9. No. 4. P. 6.)
2. 2. Исаев А.А., Бардаков С.Н., Мкртчян Л.А., Мусатова Е.В., Хмелькова Д.Н., Гусева М.В., Каймонов В.С., Яковлев И.А., Деев Р.В. 2023. Новые варианты нуклеотидных последовательностей гена DYSF, выявленные методом секвенирования нового поколения. Мед. генетика. Т. 22. № 6. С. 3. (Isaev A.A., Bardakov S.N., Mkrtchyan L.A., Musatova E.V., Khmelkova D.N., Guseva M.V., Kaimonov V.S., Yakovlev I.A., Deev R.V. 2023. New nucleotide sequence variants of the DYSF gene, identified by the next-generation sequencing. Medical Genetics. V. 22. No. 6. P. 3.)
3. 3. Старостина И.Г., Соловьева В.В., Шевченко К.Г., Деев Р.В., Исаев А.А., Ризванов А.А. 2012. с. Гены и клетки. Т.7. № 3. C. 25. (Starostina I.G, Solovyeva V.V., Shevchenko K.G. et al. 2012. (Formation of the recombinant adenovirus encoding codon-optimized dysferlin gene and analysis of the recombinant protein expression in cell culture in vitro. Cell. Transplantat. Tiss. Eng. V.7. No. 3. P. 25.)
4. 4. Яковлев И.А., Деев Р.В., Соловьева В.В., Ризванов А.А., Исаев А.А. 2016. Пред- и посттранскрипционная модификация генетической информации в программе лечения мышечных дистрофий. Гены и клетки. Т. 1 1. № 2. С. 42. (Yakovlev I.A., Deev R.V., Solovyеva V.V., Rizvanov A.A., Isaev A.A. 2016. Pre- and posttranscriptional genetic information modification in muscular dystrophy treatment. Genes Cells. V. 11. No 2. P. 42.)
5. 5. Agrawal G. Aung A., Varghese S. 2017. Skeletal muscle-on-a-chip: an in vitro model. V. 17. P. 3447. https://doi.org/10.1039/c7lc00512a
6. 6. Arab-Bafrani Z., Shahbazi-Gahrouei D., Abbasian M., Fesharaki M. 2016. Multiple MTS assay as the alternative method to determine survival fraction of the irradiated HT-29 colon cancer cells. J. Med. Signals Sens. V. 6. P. 112.
7. 7. Argov Z., Sadeh M., Mazor K., Soffer D., Kahana E., Eisenberg I., Mitrani-Rosenbaum S., Richard I., Beckmann J., Keers S., Bashir R., Bushby K., Rosenmann H. 2000. Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. Brain. V. 6. P. 1229. https://doi.org/10.1093/brain/123.6.1229
8. 8. Barthelemy F. Santoso J.W., Rabichow L., Jin R., Little I., Nelson S.F., McCain M.L., Miceli M.C. 2022. Modeling patient-specific muscular dystrophy phenotypes and therapeutic responses in reprogrammed myotubes engineered on micromolded gelatin hydrogels. Front Cell Dev Biol. V. 10: 830415. https://doi.org/10.3389/fcell.2022.830415
9. 9. Belanto J., Diaz-Perez S., Magyar C., Maxwell M., Yilmaz Y., Topp K., Boso G., Jamieson C.H., Cacalano N.A., Jamieson C.A. 2010. Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord. V. 2. P. 111. https://doi.org/10.1016/j.nmd.2009.12.003
10. 10. Bouchard C., Tremblay J.P. 2023. Portrait of dysferlinopathy: diagnosis and development of therapy. J. Clin. Med. V. 12: 6011. https://doi.10.3390/jcm12186011
11. 11. Bruge C., Geoffroy M., Benabides M., Pellier E., Gicquel E., Dhiab J., Hoch L., Richard I., Nissan X. 2022. Skeletal muscle cells derived from induced pluripotent stem cells: a platform for limb girdle muscular dystrophies. Biomed. V. 10: 1428. https://doi.org/10.3390/biomedicines10061428
12. 12. Chamberlain J.R., Chamberlain J.S. 2017. Progress toward gene therapy for duchenne muscular dystrophy. Mol. Ther. V. 5. P. 1125. https://doi.10.1016/j.ymthe.2017.02.019
13. 13. Crisafulli S., Sultana J., Fontana A., Salvo F., Messina S., Trifiro G. 2020. Global epidemiology of duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J. Rare Dis. V. 15. P. 141. https://doi.org/10.1186/s13023-020-01430-8
14. 14. Defour A., Van der Meulen J.H., Bhat R., Bigot A., Bashir R., Nagaraju K., Jaiswal J.K. 20 14. Dysferlin regulates cell membrane repair by facilitating injury-triggered acid sphingomyelinase secretion. Cell Death Dis. V. 5: 1306. https://doi.org/10.1038/cddis.2014.272
15. 15. Heidersbach A.J., Dorighi K.M., Gome J.A. 2023. A versatile, high-efficiency platform for CRISPR-based gene activation. Nat. Commun. V. 14. P. 902. https://doi.org/10.1038/s41467-023-36452-w
16. 16. Hunt C., Hartford S.A., White D., Pefanis E., Hanna T., Herman C., Wiley J., Brown H., Su Q., Xin Y., Voronin D., Nguyen H., Altarejos J., Crosby K., Haines J. et al. 2021. Tissue-specific activation of gene expression by the Synergistic Activation Mediator (SAM) CRISPRa system in mice. Nat. Commun. V. 12. P. 2770. https://doi.org/10.1038/s41467-021-22932-4
17. 17. Illarioshkin S.N., Ivanova-Smolenskaya I.A., Tanaka H., Vereshchagin N.V., Markova E.D., Poleshchuk V.V., Lozhnikova S.M., Sukhorukov V.S., Limborska S.A., Slominsky P.A., Bulayeva K.B., Tsuji S. 1996. Clinical and molecular analysis of a large family with three distinct phenotypes of progressive muscular dystrophy. Brain. V. 6. P. 1895. https://doi.org/10.1093/brain/119.6.1895
18. 18. Jean J., Lapointe M., Soucy J., Pouliot R. 2009. Development of an in vitro psoriatic skin model by tissue engineering. J. Dermatol. Sci. V. 53. P. 19. https://doi.org/10.1016/j.jdermsci.2008.07.009
19. 19. Jiang J., Sun Y., Xiao R., Wai K., Ahmad M.J., Khan F.A., Zhou H., Li Z., Zhang Y., Zhou A., Zhang S. 2019. Porcine antiviral activity is increased by CRISPRa-SAM system. Biosci. Rep. V. 8. https://doi.org/10.1042/BSR20191496
20. 20. Jensen T.I., Mikkelsen N.S., Gao Z, Foßelteder J., Pabst G., Axelgaard E., Laustsen A., König S., Reinisch A., Bak R.O. 2021. Targeted regulation of transcription in primary cells using CRISPRa and CRISPRi. Genome Res. V. 3111. P. 2120. https://doi.org/10.1101/gr.275607.121
21. 21. Johnson C.I., Argyle D.J., Clements D.N. 2016. In vitro models for the study of osteoarthritis. Vet. J. V. 209. P. 40. https://doi.org/10.1016/j.tvjl.2015.07.011
22. 22. Kabadi A.M., Thakore P.I., Vockley C.M., Ousterout D.G., Gibson T.M., Guilak F., Reddy T.E., Gersbach C.A. 2015. Enhanced MyoD-induced transdifferentiation to a myogenic lineage by fusion to a potent transactivation domain. ACS Synth. Biol. V. 6. P. 689. https://doi.org/10.1021/sb500322u
23. 23. Katt M.E., Placone A.L., Wong A.D., Xu Z.S., Searson P.C. 2016. In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform. Front. Bioeng. Biotechnol.V. 4. P. 12. https://doi.org/10.3389/fbioe.2016.00012
24. 24. Khaiboullina S.F., Martynova E.V., Bardakov S.N., Mavlikeev M.O., Yakovlev I.A., Isaev A.A., Deev R.V., Rizvanov A.A. 2017. Serum cytokine profile in a patient diagnosed with dysferlinopathy. Case Rep. Med. V. 2017: 3615354. https://doi.org/10.1155/2017/3615354
25. 25. Konermann S., Brigham M.D., Trevino A.E., Joung J., Abudayyeh O.O., Barcena C., Hsu P.D., Habib N., Gootenberg J.S., Nishimasu H., Nureki O., Zhang F. 2015. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. V. 7536. P. 583. https://doi.org/10.1038/nature14136
26. 26. Lek A., Evesson F. J., Sutton R. B., North K. N., Cooper S.T. 2012. Ferlins: regulators of vesicle fusion for auditory neurotransmission, receptor trafficking and membrane repair. Traffic. V. 13. P. 185. https://doi.org/10.1111/j.1600-0854.2011.01267.x
27. 27. Leshinsky-Silver E., Argov Z., Rozenboim L., Cohen S., Tzofi Z., Cohen Y., Wirguin Y., Dabby R., Lev D., Sadeh M. 2007. Dysferlinopathy in the jews of the caucasus: a frequent mutation in the dysferlin gene. Neuromus. Disord. V. 17. P. 950. https://doi.org/10.1016/j.nmd.2007.07.010
28. 28. Liu W., Pajusalu S., Lake N.J., Zhou G., Ioannidis N., Mittal P., Johnson N.E., Weihl C.C., Williams B.A., Albrecht D.E., Rufibach L.E., Lek M. 2019. Estimating prevalence for limb-girdle muscular dystrophy based on public sequencing databases. Genet. Med. V. 21. P. 2512. https://doi.10.1038/s41436-019-0544-8
29. 29. Luo N., Zhong W., Li J., Zhai Z., Lu J., Dong R. 2022. Targeted activation of HNF4α/HGF1/FOXA2 reverses hepatic fibrosis via exosome-mediated delivery of CRISPR/dCas9-SAM system. Nanomed. V. 17. P. 1411. https://doi.org/10.10.2217/nnm-2022-0083
30. 30. Mamchaoui K., Trollet C., Bigot A., Negroni E., Chaouch S., Wolff A., Kandalla P.K., Marie S., Di Santo J., St. Guily J.L., Muntoni F., Kim J., Philippi S., Spuler S., Levy N., et al. 2011. Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skeletal Muscle. V. 1. P. 34. https://doi.org/10.1186/2044-5040-1-34
31. 31. Rossi R., Torelli S., Ala P., Weston W., Morgan J., Malhotra J., Muntoni F. 2023. MyoD-induced reprogramming of human fibroblasts and urinary stem cells in vitro: protocols and their applications. Front. Physiol. V. 14: 1145047. https://doi.org/10.3389/fphys.2023.1145047
32. 32. Salmon P., Trono D. 2006. Production and titration of lentiviral vectors. Curr. Protoc. Neurosci. V. 4. U. 4.21. https://doi.org/10.0.3.234/0471142301.ns0421s53
33. 33. Salari N., Fatahi B., Valipour E., Kazeminia M., Fatahian R., Kiaei A., Shohaimi S., Mohammadi M. 2022. Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis. J. Orthop Surg. Res. V. 17. P. 96. https://doi.org/10.1186/s13018-022-02996-8
34. 34. Shin M.K., Bang J.S., Lee J.E., Tran H.D., Park G., Lee D.R., Jo J. 2022. Generation of skeletal muscle organoids from human pluripotent stem cells to model myogenesis and muscle regeneration. Int. J. Mol. Sci. V. 23. N. 5108. https://doi.org/10.3390/ijms23095108
35. 35. Stoppelkamp S., Bell H.S., Palacios-Filardo J., Shewan D.A., Riedel G., Platt B. 2011. In vitro modelling of Alzheimer’s disease: degeneration and cell death induced by viral delivery of amyloid and Tau. Exp Neurol. V. 229. P. 226. https://doi.org/10.1016/j.expneurol.2011.01.018
36. 36. Stewart S.A., Dykxhoorn D.M., Palliser D., Mizuno H., Yu E.Y., An D.S., Sabatini D.M., Chen I.S., Hahn W.C., Sharp P.A., Weinberg R.A., Novina C.D. 2003. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. V. 4. P. 493. https://doi.org/10.1261/rna.2192803.
37. 37. Szulc J., Wiznerowicz M., Sauvain M.O., Trono D., Aebischer P. 2006. A versatile tool for conditional gene expression and knockdown. Nat. Methods. V. 3. P. 10. https://doi.org/10.1038/nmeth846
38. 38. Thomas P., Smart T.G. 2005. HEK293 cell line: A vehicle for the expression of recombinant proteins. J. Pharmacol. Toxicol. Methods. V. 51. P. 187. https://doi.org/10.1016/j.vascn.2004.08.014
39. 39. Tominaga K., Tominaga N., Williams E.O., Rufibach L., Schöwel V., Spuler S., Viswanathan M., Guarente L.P. 2021. 4-Phenylbutyrate restores localization and membrane repair to human dysferlin mutations. iScience. V. 25. N. 103667. https://doi.org/10.1016/j.isci.2021.103667
40. 40. Tumiati LC., Mickle D.A.G., Weisel R.D., Williams W.G., Li R.K. 1994. An in vitro model to study myocardial ischemic injury. J. Tiss. Culture Methods. V. 16. P. 1. https://doi.org/10.1007/BF01404830
41. 41. Ulman A., Kot M., Skrzypek K., Szewczyk B., Majka M. 2021. Myogenic differentiation of ips cells shows different efficiency in simultaneous comparison of protocols. Cells. V. 10. P. 1671. https://doi.org/10.3390/cells10071671
42. 42. Umakhanova Z.R., Bardakov S.N., Mavlikeev M.O., Chernova O.N., Magomedova R.M., Akhmedova P.G., Yakovlev I.A., Dalgatov G.D., Fedotov V.P., Isaev A.A., Deev R.V. 2017. Twenty-year clinical progression of dysferlinopathy in patients from Dagestan. Front. Neurol. V. 8. P. 77. https://doi.org/10.3389/fneur.2017.00077
43. 43. Urtizberea J.A., Bassez G., Leturcq F., Nguyen K., Krahn M., Levy N. 2008. Dysferlinopathies. Neurol. India. V. 3. P. 289. https://doi.org/10.4103/0028-3886.43447
44. 44. Vunjak Novakovic G., Eschenhagen T., Mummery C. 2014. Myocardial tissue engineering: in vitro models. Cold Spring Harb. Perspect Med. V. 4: a014076. https://doi.org/10.1101/cshperspect.a014076
45. 45. Wang H., La Russa M., Qi LS. 2016. CRISPR/Cas9 in genome editing and beyond. Annu. Rev. Biochem. V. 85. P. 227. https://doi.org/10.1146/annurev-biochem-060815-014607
46. 46. Wang C.H., Lundh M., Fu A., Kriszt R., Huang T.L., Lynes M.D., Leiria L.O., Shamsi F., Darcy J., Greenwood B.P., Narain N.R., Tolstikov V., Smith K.L., Emanuelli B., Chang Y.T., et al. 2020. CRISPR-engineered human brown-like adipocytes prevent diet-induced obesity and ameliorate metabolic syndrome in mice. Sci. Transl. Med. V. 26: eaaz8664. https://doi.org/10.1126/scitranslmed.aaz8664
47. 47. Xiong K., Zhou Y., Hyttel P., Bolund L., Freude K.K., Luo Y. 2016. Generation of induced pluripotent stem cells (iPSCs) stably expressing CRISPR-based synergistic activation mediator (SAM). Stem Cell Res. V. 17. P. 665. https://doi.org/10.1016/j.scr.2016.10.011
48. 48. Zhang Y.S., Oklu R., Albadawi H. 2017. Bioengineered in vitro models of thrombosis: methods and techniques. Cardiovasc. Diagn. Ther. V. 7. P. 329. https://doi.org/10.21037/cdt.2017.08.08
49. 49. Zorin V.L., Pulin A.A., Eremin I.I., Korsakov I.N., Zorina A.I., Khromova N.V., Sokova O.I., Kotenko K.V., Kopnin P.B. 2017. Myogenic potential of human alveolar mucosa derived cells. Cell Cycle. V. 16. P. 545. https://doi.org/10.1080/15384101.2017.1284714